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Respiratory Complications of
Parkinson’s Disease
Holly Shill, M.D.1 and Mark Stacy, M.D.2

ABSTRACT

Downloaded by: Elsevier Bibliographic Databases. Copyrighted material.

Patients with Parkinson’s disease are at risk for pulmonary complications as a
consequence of both the underlying disease pathology and the side effects of medication.
Degeneration of the substantia nigra and subsequent loss of dopaminergic neurons may
produce changes in ventilatory parameters. Upper airway obstruction and chest wall restriction are both common, and both may respond to levodopa. However, therapy for
Parkinson’s may also contribute to pulmonary morbidity. Overtreatment with levodopa
causes respiratory dyskinesia that may be difficult to differentiate from complications of
the disease itself. Therapy with ergot derivatives may cause pleuropulmonary fibrosis.
Pneumonia resulting from the respiratory complications remains a significant cause of
morbidity and mortality in Parkinson’s disease.
KEYWORDS: Parkinson’s disease, dopaminergic, levodopa, chest wall rigidity,

pulmonary complications

Objectives: Upon completion of this article, the reader should: (1) be able to discuss the common respiratory complications of
Parkinson’s disease; (2) know what pharmacotherapies are available to treat these complications; and (3) know potential complications of the medications used to treat Parkinson’s.
Accreditation: The University of Michigan is accredited by the Accreditation Council for Continuing Medical Education to sponsor
continuing medical education for physicians.
Credits: The University of Michigan designates this educational activity for a maximum of 1.0 hour in category one credits toward
the AMA Physicians Recognition Award.

P

arkinson’s disease (PD) results from degeneration of the substantia nigra and loss of dopaminergic
neurons. The cardinal manifestations of PD include
tremor, rigidity, bradykinesia, and loss of postural reflexes. These abnormalities are not limited to the extremities but also affect striated muscle within the
upper airway and chest wall. Noting this association in
his early description of PD, James Parkinson described
a man who, in addition to the cardinal features of the
disease, “fetched his breath rather hard.”1 Medications
used to treat parkinsonism are also associated with vari-

ous pulmonary complications. Awareness of the spectrum of pulmonary manifestations of PD may allow
clinicians to better care for their patients with this degenerative condition.

UPPER AIRWAY OBSTRUCTION
The most common manifestation of upper airway involvement in PD patients is hypophonia.2 Reasonable
estimates suggest that approximately 70% of PD patients are bothered by this symptom. Hypophonia re-
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sults from both rigidity and fatigability of the thyroarytenoid muscles during vocalization.3,4 Although the
neurological substrate of hypophonia has not been defined, a central cause is likely because lesions within the
basal ganglia may adversely affect speech volume.5,6
Treatment with anti-parkinson medications may partially alleviate the hypophonia, and speech therapy is
generally recommended. Collagen injection into the
vocal cords has also been tried with some success.7
Spirometry reveals that a high percentage of PD
patients have upper airway obstruction (UAO), often
in asymptomatic individuals.8 This silent abnormality,
coupled with the impaired cough reflex in PD patients,9
may contribute to complications such as aspiration pneumonia. Two main types of UAO have been described.
The first, termed respiratory flutter, is characterized by a
pattern of UAO with superimposed rapid oscillations of
the supraglottic structures and vocal cords that are apparent on a flow volume loop.10 These rhythmic oscillations are time-locked to the 4 to 8 Hz resting tremor in
PD patients and can be verified by endoscopy. The second pattern of UAO is characterized by irregular, abrupt
changes on the flow-volume loop, at times indicating
complete obstruction.10 Rigidity and hypokinesia of both
the upper airway and the chest wall are thought to contribute to this second pattern. As with hypophonia,
UAO is thought to be a direct consequence of the pathology within the basal ganglia causing irregularities in
agonist and antagonist respiratory muscle actions.
Both the overall prevalence of upper airway symptoms and physiological evidence for UAO in PD appear
to be diminishing, which may reflect a therapeutic benefit of anti-parkinson medications on pulmonary status.10–12 However, the prevalence of upper airway changes
in PD may be decreasing simply because diagnostic accuracy is improving, and patients with UAO due to other
causes are being more reliably excluded. Early reports
may have demonstrated high percentages of UAO due to
inclusion of patients with postencephalitic parkinsonsism, a condition that is clinically distinct from idiopathic
PD and is known to produce pulmonary problems.13 Previous findings of increased obstructive abnormalities may
also be due to poor control of factors such as smoking and
chronic bronchitis.11
Two recent studies using similar, carefully controlled populations of patients reported substantially
different rates of baseline UAO.12,14 The first study
found restrictive changes as the primary abnormality,
seen in 85% of patients, and only one of 63 subjects had
UAO. The second study noted that UAO was more
prominent, with abnormal inspiratory and expiratory
flow rates seen in 62% of patients. A major difference
between these studies was that the first studied patients
while they continued their medications, whereas the
second held the medications. This suggests that UAO
may be acutely sensitive to dopaminergic stimulation.

Additional studies have unequivocally demonstrated the favorable response of UAO to anti-parkinson
medications. A study using spirometry in idiopathic PD
compared patients on and off intravenous apomorphine
(a short-acting dopamine agonist) and showed that UAO
was particularly sensitive to dopaminergic stimulation.15
Improvement was seen primarily in inspiratory and expiratory flow rates with only a minor improvement in maximal inspiratory pressure. Total respiratory resistance remained normal and did not change with apomorphine. A
recent placebo-controlled trial using oral levodopa has
also confirmed this finding.16 In this latter study, patients
who met criteria for UAO demonstrated an improved
“sawtooth” flow-volume loop pattern as well as enhanced
expiratory flow rates with levodopa treatment.
More evidence of the effectiveness of antiparkinson medications in ameliorating UAO derives
from the observation that acute UAO with stridor and
respiratory failure occasionally develops when these
medications are manipulated or withdrawn.17–20 This is
particularly important during the perioperative period
or times of critical illness, when the inability to use typical oral medications, such as levodopa, can promote
these complications. Intravenous apomorphine has been
proposed as a useful intervention in this situation21 but
has limited availability in the United States. Early postoperative reinstitution of oral therapy, particularly
around the time of ventilator weaning, may help to reduce this type of complication. Similarly, rapid changes
in medication dosage should be avoided.

RESTRICTIVE ABNORMALITIES
Like upper airway abnormalities, restriction within the
respiratory system is also thought to reflect the primary
pathology of PD. For years, this was considered to be
the only respiratory dysfunction present.22–24 This probably reflected the more advanced disability of patients
with PD prior to the widespread use of levodopa, so
that the restrictive abnormalities were more obvious.
Spirometric findings in those early patients were similar
to those with peripheral neuromuscular conditions and
this was interpreted as “muscle weakness.”22 Because
myopathic weakness is not a feature of PD, most clinicians would reinterpret this finding as disordered central respiratory control and muscle fatigability, leading
to apparent chest wall muscle weakness.
The restrictive changes of PD are also thought to
be due to loss of chest wall compliance secondary to
severe rigidity. Electromyographic assessment of the
respiratory musculature supports this hypothesis.25 In
addition, longstanding chest wall rigidity may lead to
kyphoscoliosis, substantially reducing lung volumes and
contributing to restrictive ventilation.14
With the effective therapies of PD now available,
restrictive changes are thought to contribute less to early
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SLEEP APNEA
Sleep apnea is not thought to be associated with idiopathic PD.27 However, a similar condition, now termed
multiple system atrophy (MSA), is associated with a variety of nonextrapyramidal findings that may include
sleep apnea. MSA is an encompassing term that currently includes diagnoses such as Shy-Drager syndrome,
olivopontocerebellar atrophy, and striatonigral degeneration. MSA may have signs and symptoms of autonomic
disturbance, spasticity, ataxia, neuropathy, and dementia,
in addition to bradykinesia and rigidity. The parkinsonism in MSA is generally poorly responsive to medication. MSA is associated with a shorter life expectancy
compared with idiopathic PD, possibly due to the concurrence of nocturnal stridor and central sleep apnea.28
The pathophysiology of the sleep apnea in MSA is unknown, but may reflect the impaired autonomic control
of the dorsal medullary respiratory center.29 This type of
UAO is generally unresponsive to dopaminergic modulation and is better treated by tracheostomy.

ACUTE COMPLICATIONS WITH
MEDICATIONS
Although levodopa therapy improves respiratory and
motor function in PD patients, development of dyskinesias (e.g., abnormal involuntary movements well recognized in advancing PD), may also affect ventilation.
Patients with respiratory dyskinesias may complain of
dyspnea and chest pain shortly after levodopa administration.30,31 Serial pulmonary function tests and inductive plethysmography demonstrate the appearance of
rapid shallow breathing and a decline in pulmonary
function. These are associated with the clinical onset of
limb and orofacial dykinesias that are typical of peakdose, levodopa-induced dyskinesias. Because complaints
of acute chest pain and shortness of breath in this older
population might otherwise lead to an extensive evaluation for cardiac and pulmonary disorders, this side effect of treatment should be considered early in the differential diagnosis. A recession of the dyskinesias with
medication withdrawal or dosage reduction is helpful
diagnostically.
In more advanced patients, a wearing-off phenomenon between levodopa doses may induce acute

pulmonary complaints, including dystonia of the laryngeal muscles causing stridor.32 Chest wall tightness with
shortness of breath and anxiety may also occur, which
superficially resembles a panic attack.33 This may be due
in part to a psychological response to the sudden appearance of chest wall rigidity that causes an acute restrictive condition, but the reaction is not entirely psychological. These types of wearing-off phenomena are
treated similarly to other motor fluctuations.34 Generally, the strategy is to smooth the levodopa response by
providing appropriate dose overlap or adding a dopamine agonist or catechol-o-methyltransferase inhibitor
to provide longer-acting therapy.

PLEUROPULMONARY FIBROSIS
Another complication of PD therapy is the development of pleuropulmonary fibrosis induced by dopamine
agonists like bromocriptine.35,36 This is thought to be a
specific response to the ergot dopamine agonists and,
therefore, is not seen with newer agents like pramipexole and ropinerole. Symptoms include dyspnea, pleuritic
pain, and a nonproductive cough. Pulmonary infiltrates
and pleural effusions are seen on the chest radiograph.
The sedimentation rate may be elevated and the pleural
fluid may show inflammatory cells with a predominance
of eosinophils. Although initially believed to be present
in 2 to 5% of patients on the ergot agents, this condition
is now thought to be exceedingly rare.37,38 Discontinuing the dopamine agonists usually reverses the abnormalities. The pathophysiology for this entity is poorly
understood but may reflect serotonergic activation triggering an inflammatory response.39 More recently, a
link between this response and prior exposure to asbestos was postulated.40

EXERCISE CAPACITY AND
VENTILATORY STATUS
Although most patients with respiratory impairment associated with PD are asymptomatic, these studies suggest increased disability corresponding to the level of
respiratory dysfunction.26 Whether the respiratory abnormalities contribute to the disabilities or are simply
markers for more advanced disease is unknown.8 However, short-term pulmonary rehabilitation and exercise
programs may improve some respiratory parameters and
exercise capacity in ambulatory PD patients, with the
expectation that quality of life would be improved, as
well.41,42 These data, coupled with evidence suggesting
abnormalities in repetitive ventilatory tasks in early patients,43 support the concept that the already high prevalence of abnormal resting pulmonary function tests in
more advanced PD patients may still underestimate the
importance of respiratory difficulties in this population.
It is prudent to consider abnormal ventilatory status in
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pulmonary disability. However, restrictive disease correlates with motor hallmarks of more advanced disease
such as falls and gait freezing.26 Because these motor
manifestations are less responsive to dopaminergic stimulation, this suggests that the restrictive process may
eventually become unresponsive to medical management. Also, kyphoscoliosis associated with PD rarely
improves with medical management, and physical therapy interventions are recommended.
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any PD patient who complains of excessive fatigue and
poor exercise tolerance because these complaints might
be amenable to nonpharmacological therapy. Arterial
blood gases may occasionally detect hypoventilation, although studies on the response of Parkinson’s patients to
noninvasive ventilation are lacking.

ASPIRATION PNEUMONIA
As Parkinson’s disease progresses, respiratory impairment becomes more severe. Mastication is affected,
brady- and dyskinesias impair the swallowing mechanism, and aspiration becomes a problem. Switching to a
soft mechanical diet, and the input of a speech and
swallowing therapist may help. Patients are taught to
chew carefully and to maintain a chin tuck position
while swallowing. However, these measures are temporizing, and patients may have difficulty learning the
swallowing techniques if their Parkinson’s is complicated by dementia.
Eventually, the cough mechanism becomes
weakened by chest wall rigidity, dyskinesias, and upper
airway dysfunction. This, in combination with the
swallowing difficulties, creates a lethal situation, leading inevitably to aspiration pneumonia and death. Tracheostomy can be used to treat the swallowing and
cough impairment but is not recommended in patients
with advanced disease, particularly if complicated by
dementia.

CONCLUSIONS
Pneumonia remains the most frequent cause of death in
PD patients despite the development of effective therapeutic regimens over the past three decades. The reason
for the lack of a greater therapeutic effect is multifactorial. The primary pathological defect in PD, the destruction of the substantia nigra and loss of dopaminergic
neurons, combined with the side effects of the medications used to treat the condition, affect the pulmonary
system at multiple levels. These defects contribute to
impairment of upper airway function as well as chest
wall compliance and lead to problems with swallowing
and cough that predispose to the development of pneumonia, the leading cause of mortality in PD. In addition
to optimal medical therapy that helps to improve upper
airway function, measures aimed at enhancing cough
and reducing the risk of aspiration may help. Ultimately,
further advances in the medical therapy of PD should
reduce the morbidity and mortality attributable to pulmonary dysfunction, leading to better outcomes for individuals suffering from this progressive neurodegenerative condition.
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